Key Stats
Alcon stands as the global leader in eye care products and medical devices with operations spanning 75 countries. The company specializes in developing surgical equipment, contact lenses, and pharmaceutical solutions for treating cataracts, glaucoma, retinal diseases, and refractive errors.
Founded in 1945 in Fort Worth, Texas, Alcon has evolved from a small pharmacy into a multibillion dollar corporation. The organization maintains dual headquarters in Geneva, Switzerland, and Fort Worth, Texas, where it employs approximately 4,500 people at its operational base.
Following its spinoff from Novartis in April 2019, Alcon operates as an independent publicly traded company on both the Swiss Exchange and New York Stock Exchange under the ticker symbol ALC. The company commits substantial resources to research and development, maintaining one of the largest R&D investments in the eye care industry.
Alcon History
Alcon Co-founders
Alcon Revenue
Alcon generated revenue of 9.8 billion dollars in full year 2024, representing a 5 percent increase on a reported basis and 6 percent growth on a constant currency basis compared to 2023.
Alcon Marketcap
Alcon maintains a market capitalization of approximately 37.87 billion dollars as of September 2024, demonstrating the company’s strong position in the global eye care market.
Alcon Acquisitions
Alcon has pursued strategic acquisitions to strengthen its portfolio across surgical, pharmaceutical, and vision care segments. The company acquired Ivantis in 2021 for at least 475 million dollars, adding glaucoma surgery stent technology to its offerings. This acquisition brought the Hydrus Microstent into the surgical glaucoma portfolio, leveraging Alcon’s global commercial footprint.
In August 2022, Alcon completed the acquisition of Aerie Pharmaceuticals for approximately 770 million dollars to enhance its ophthalmic pharmaceutical business. This transaction added commercial products Rocklatan and Rhopressa for glaucoma treatment, along with AR-15512, a Phase 3 product candidate for dry eye disease. The acquisition expanded Alcon’s presence in the 20 billion dollar global ophthalmic pharmaceutical category.
The company also acquired pharmaceutical products from Kala Pharmaceuticals in May 2022 for 60 million dollars, obtaining Eysuvis for dry eye treatment and Inveltys for postoperative inflammation. Earlier in 2021, Alcon obtained exclusive U.S. commercialization rights to Simbrinza from Novartis for 355 million dollars.
In March 2025, Alcon announced plans to acquire LENSAR for 356 million dollars plus contingent payments. The acquisition includes the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and LENSAR legacy laser system. The transaction aims to expand global access to advanced femtosecond laser technology for cataract surgery, with closing expected in the second half of 2025.
Beyond these major acquisitions, Alcon acquired Belkin Vision in July 2024 and announced plans to acquire LumiThera in September 2025. The company has completed 17 acquisitions with an average acquisition amount of 483 million dollars, focusing primarily on ophthalmology and wearable technology sectors to strengthen its market position.
Alcon Competitors
Alcon faces competition from several major players in the global eye care market who offer similar surgical equipment, contact lenses, and pharmaceutical products.
| Competitor | Primary Focus |
|---|---|
| Johnson & Johnson Vision | Contact lenses, surgical equipment, vision care solutions |
| CooperVision | Contact lenses, specialty eye care products |
| Bausch + Lomb | Contact lenses, pharmaceuticals, surgical devices |
| Carl Zeiss Meditec | Ophthalmic diagnostic equipment, surgical microscopes |
| EssilorLuxottica | Eyewear, prescription lenses, optical retail |
| Hoya Corporation | Optical lenses, medical equipment |
| Menicon | Contact lenses, lens care products |
| STAAR Surgical | Implantable lenses, refractive surgery |
| Sight Sciences | Surgical glaucoma devices |
| The Cooper Companies | Medical devices, contact lenses |
FAQs
What does Alcon manufacture?
Alcon manufactures surgical equipment including phacoemulsification devices and intraocular lenses, contact lenses such as Dailies and Air Optix brands, and ophthalmic pharmaceuticals for treating glaucoma and dry eye. The company also produces lens care solutions and diagnostic instruments.
When was Alcon founded?
Alcon was founded in 1945 by pharmacists Robert Alexander and William Conner in Fort Worth, Texas. The company incorporated as Alcon Laboratories in 1947 with William Conner serving as the first president of the organization.
Who owns Alcon now?
Alcon operates as an independent publicly traded company since its spinoff from Novartis on April 9, 2019. The company trades on the Swiss Exchange and New York Stock Exchange under ticker symbol ALC, with shares owned by public investors.
Where is Alcon headquarters located?
Alcon maintains dual headquarters with its global headquarters in Geneva, Switzerland, and its main operational base in Fort Worth, Texas, United States. The Fort Worth facility employs approximately 4,500 people and serves as the company’s largest location.
How many employees work at Alcon?
Alcon employs more than 25,599 associates globally as of December 2024, representing a 2.4 percent increase from the previous year. The workforce operates across 75 countries, serving customers in over 140 nations worldwide.
